1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Retinopathy - Pipeline Review, H2 2013

Retinopathy - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 48 pages

Retinopathy - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Retinopathy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinopathy. Retinopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Retinopathy.
- A review of the Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Retinopathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Retinopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Retinopathy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Retinopathy - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Retinopathy Overview 6
Therapeutics Development 7
Pipeline Products for Retinopathy - Overview 7
Pipeline Products for Retinopathy - Comparative Analysis 8
Retinopathy - Therapeutics under Development by Companies 9
Retinopathy - Therapeutics under Investigation by Universities/Institutes 10
Retinopathy - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Retinopathy - Products under Development by Companies 14
Retinopathy - Products under Investigation by Universities/Institutes 15
Retinopathy - Companies Involved in Therapeutics Development 16
GTx, Inc. 16
Affichem 17
SIFI S.p.A 18
TWi Pharmaceuticals, Inc. 19
Retinopathy - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Assessment by Therapeutic Class 29
Drug Profiles 32
interferon gamma-1b - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
rituximab - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
AC-301 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Beta-LGND2 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Mutants Of Pigment Epithelium Derived Factor - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
AF-243 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
SF-113 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
SF-106 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Retinopathy - Dormant Projects 42
Retinopathy - Discontinued Products 43
Retinopathy - Product Development Milestones 44
Featured News and Press Releases 44
May 08, 2012: Gene Signal Presents Preclinical Data Of Aganirsen At ARVO Annual Meeting 44
Mar 19, 2012: QLT Receives Orphan Drug Designation For Visudyne For Treatment of Central Serous Chorioretinopathy 44
Feb 14, 2012: Gene Signal And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retinal Neovascular Disease 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48



List of Tables

Number of Products under Development for Retinopathy, H2 2013 7
Number of Products under Development for Retinopathy - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Comparative Analysis by Unknown Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
Retinopathy - Pipeline by GTx, Inc., H2 2013 16
Retinopathy - Pipeline by Affichem, H2 2013 17
Retinopathy - Pipeline by SIFI S.p.A, H2 2013 18
Retinopathy - Pipeline by TWi Pharmaceuticals, Inc., H2 2013 19
Assessment by Monotherapy Products, H2 2013 20
Number of Products by Stage and Target, H2 2013 22
Number of Products by Stage and Mechanism of Action, H2 2013 24
Number of Products by Stage and Route of Administration, H2 2013 26
Number of Products by Stage and Molecule Type, H2 2013 28
Number of Products by Stage and Therapeutic Class, H2 2013 31
Retinopathy - Dormant Projects, H2 2013 42
Retinopathy - Discontinued Products, H2 2013 43



List of Figures

Number of Products under Development for Retinopathy, H2 2013 7
Number of Products under Development for Retinopathy - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 20
Number of Products by Top 10 Target, H2 2013 21
Number of Products by Stage and Top 10 Target, H2 2013 22
Number of Products by Top 10 Mechanism of Action, H2 2013 23
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 24
Number of Products by Top 10 Route of Administration, H2 2013 25
Number of Products by Stage and Top 10 Route of Administration, H2 2013 26
Number of Products by Top 10 Molecule Type, H2 2013 27
Number of Products by Stage and Top 10 Molecule Type, H2 2013 28
Number of Products by Top 10 Therapeutic Class, H2 2013 29
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 30



Companies Mentioned

GTx, Inc.
Affichem
SIFI S.p.A
TWi Pharmaceuticals, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Ophthalmology Drug Development Pipeline Review, 2016

Ophthalmology Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Ophthalmology Drug Development Pipeline Review, 2016 Summary Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, ...

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016’, provides in depth analysis on Adenosine Recepto ...

Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Review, H2 2016

Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.